Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more
Hybio Pharmaceutical (300199) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.177x
Based on the latest financial reports, Hybio Pharmaceutical (300199) has a cash flow conversion efficiency ratio of 0.177x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥117.78 Million) by net assets (CN¥666.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hybio Pharmaceutical - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hybio Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hybio Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
0.029x |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
-0.032x |
|
Hansol Chemica
KO:014680
|
0.061x |
|
Qingdao East Steel Tower Stock Co Ltd
SHE:002545
|
0.055x |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
0.053x |
|
Talos Energy
NYSE:TALO
|
0.048x |
|
Zhe Jiang Dong Ri Ltd Co
SHG:600113
|
0.011x |
|
nCino Inc
NASDAQ:NCNO
|
0.005x |
Annual Cash Flow Conversion Efficiency for Hybio Pharmaceutical (2007–2024)
The table below shows the annual cash flow conversion efficiency of Hybio Pharmaceutical from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥597.05 Million | CN¥164.71 Million | 0.276x | +6209.36% |
| 2023-12-31 | CN¥783.21 Million | CN¥-3.54 Million | -0.005x | -137.05% |
| 2022-12-31 | CN¥1.30 Billion | CN¥15.81 Million | 0.012x | -87.19% |
| 2021-12-31 | CN¥1.65 Billion | CN¥156.83 Million | 0.095x | +232.72% |
| 2020-12-31 | CN¥1.68 Billion | CN¥47.99 Million | 0.029x | -38.96% |
| 2019-12-31 | CN¥2.23 Billion | CN¥104.64 Million | 0.047x | +238.15% |
| 2018-12-31 | CN¥3.39 Billion | CN¥47.00 Million | 0.014x | -74.81% |
| 2017-12-31 | CN¥3.88 Billion | CN¥213.74 Million | 0.055x | -33.09% |
| 2016-12-31 | CN¥3.60 Billion | CN¥296.41 Million | 0.082x | +56.20% |
| 2015-12-31 | CN¥2.64 Billion | CN¥138.84 Million | 0.053x | -55.53% |
| 2014-12-31 | CN¥1.30 Billion | CN¥153.43 Million | 0.118x | -13.29% |
| 2013-12-31 | CN¥1.12 Billion | CN¥153.48 Million | 0.137x | +59.09% |
| 2012-12-31 | CN¥1.02 Billion | CN¥87.19 Million | 0.086x | +15.57% |
| 2011-12-31 | CN¥976.09 Million | CN¥72.48 Million | 0.074x | -75.48% |
| 2010-12-31 | CN¥180.59 Million | CN¥54.69 Million | 0.303x | +48.18% |
| 2009-12-31 | CN¥127.74 Million | CN¥26.11 Million | 0.204x | -55.67% |
| 2008-12-31 | CN¥99.23 Million | CN¥45.75 Million | 0.461x | -54.21% |
| 2007-12-31 | CN¥48.70 Million | CN¥49.04 Million | 1.007x | -- |